



Viktor von Wyl

Kontakt

Viktor von Wyl

Publikationen (33)

Daniore P, Moser A, Höglinger M, Probst-Hensch N, Imboden M, Vermes T, Keidel D, Bochud M, Ortega Herrero N, Baggio S, Chocano-Bedoya P, Rodondi N, Tancredi S, Wagner C, Cullati S, Stringhini S, Nusslé S, Veys-Takeuchi C, Zuppinger C, Harju E, Michel G, Frank I, Kahlert C, Albanese E, Crivelli L, Levati S, Amati R, Kaufmann M, Geigges M, Ballouz T, Frei A, Fehr J, von Wyl V. Interplay of Digital Proximity App Use and SARS-CoV-2 Vaccine Uptake in Switzerland: Analysis of Two Population-Based Cohort Studies. *Int J Public Health* 2023; 68:1605812.

Harju E, Speierer A, Jungo K, Levati S, Baggio S, Tancredi S, Noor N, Rodondi P, Cullati S, Imboden M, Keidel D, Witzig M, Frank I, Kohler P, Kahlert C, Crivelli L, Amati R, Albanese E, Kaufmann M, Frei A, von Wyl V, Puhan M, Probst-Hensch N, Michel G, Rodondi N, Chocano-Bedoya P. Changes in Healthcare Utilization During the COVID-19 Pandemic and Potential Causes—A Cohort Study From Switzerland. *Int J Public Health* 2023; 68:1606010.

Sabatini S, Kaufmann M, Fadda M, Tancredi S, Noor N, Van Der Linden B, Cullati S, Frank I, Michel G, Harju E, Luedi C, Frei A, Ballouz T, Menges D, Fehr J, Kohler P, Kahlert C, Scheu V, Ortega N, Chocano-Bedoya P, Rodondi N, Stringhini S, Baysson H, Lorthe E, Zufferey M, Suggs L, Albanese E, Vincentini J, Bochud M, d'Acremont V, Nusslé S, Imboden M, Keidel D, Witzig M, Probst-Hensch N, von Wyl V. Factors Associated With COVID-19 Non-Vaccination in Switzerland: A Nationwide Study. *Int J Public Health* 2023; 68:1605852.

Tancredi S, Ulyte A, Wagner C, Keidel D, Witzig M, Imboden M, Probst-Hensch N, Amati R, Albanese E, Levati S, Crivelli L, Kohler P, Cusini A, Kahlert C, Harju E, Michel G, Luedi C, Ortega N, Baggio S, Chocano-Bedoya P, Rodondi N, Ballouz T, Frei A, Kaufmann M, von Wyl V, Lorthe E, Baysson H, Stringhini S, Schneider V, Kaufmann L, Wieber F, Volken T, Zysset A, Dratva J, Cullati S, Corona Immunitas Research Group. Changes in socioeconomic resources and mental health after the second COVID-19 wave (2020–2021): a longitudinal study in Switzerland. *Int J Equity Health* 2023; 22:51.

Speierer A, Baysson H, Lorthe E, Pennacchio F, Frei A, Kaufmann M, Geigges M, West E, Schwab N, Cullati S, Chiolero A, Kahlert C, Stringhini S, Vollrath F, Probst-Hensch N, Rodondi N, Puhan M, Salberg É, Tall I, d'Acremont V, Chocano-Bedoya P, Anker D, Schmid A, Keidel D, Vermes T, Imboden M, Levati S, Franscella G, Corna L, Amati R, Harju E, Luedi C, Michel G, Veys-Takeuchi C, Zuppinger C, Nusslé S, von Wyl V. The Corona Immunitas Digital Follow-Up eCohort to Monitor Impacts of the SARS-CoV-2 Pandemic in Switzerland: Study Protocol and First Results. *Int J Public Health* 2022; 67:1604506.

Rodgers S, Calabrese P, Ajdacic-Gross V, Steinemann N, Kaufmann M, Salmen A, Manjaly Z, Kesselring J, Kamm C, Kuhle J, Chan A, Gobbi C, Zecca C, Müller S, von Wyl V. Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. *J Psychosom Res* 2021; 144:110402.

Kaufmann M, Puhan M, Salmen A, Kamm C, Manjaly Z, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR). 60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. *Front Neurol* 2020; 11:156.

Barin L, Kamm C, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan M, von Wyl V, Swiss Multiple Sclerosis Registry. How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. *Mult Scler* 2019; 26:489–500.

Puhan M, Steinemann N, Kamm C, Müller S, Kuhle J, Kurmann R, Calabrese P, Kesselring J, von Wyl V, Swiss Multiple Sclerosis Registry Smsr. A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. *Swiss Med Wkly* 2018; 148:w14623.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Calmy A, Furrer H, Battegay M, Cavassini M, Aubert V, Klimkait T, Yerly S, Böni J, Kouyos R, Yang W, von Wyl V. Emergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland – a 15 year prospective cohort analysis. *Clin Infect Dis* 2016

Metzner K, Günthard H, Weber R, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Hirsch H, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, von Wyl V, Scherrer A, the Swiss HIV Cohort Study. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. *AIDS* 2014; 28:2231-2239.

Drescher S, Kouyos R, Günthard H, Ledergerber B, Vernazza P, Bernasconi E, Cavassini M, Ambrosioni J, Battegay M, Furrer H, Taffé P, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Yang W, von Wyl V, Swiss HIV Cohort Study. Treatment-naïve individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. *Clin Infect Dis* 2013; 58:285-94.

von Wyl V, Glass T, Bucher H, Günthard H, Aubert V, Böni J, Bernasconi E, Calmy A, Cavassini M, Furrer H, Nicca D, Yerly S, Klimkait T, Swiss HIV Cohort Study. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. *PLoS one* 2013; 8:e77691.

Beerenwinkel N, Günthard H, Celleraï C, Klimkait T, Böni J, Yerly S, Bernasconi E, Vernazza P, Cavassini M, Hirschel B, Battegay M, Furrer H, von Wyl V, Knupfer P, Schuhmacher H, Montazeri H, Swiss HIV Cohort Study. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. *PLoS Comput Biol* 2013; 9:e1003203.

Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. *J Infect Dis* 2013; 208:1102-12.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Celleraï C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. *PLoS one* 2012; 7:e37983.

von Wyl V, Günthard H, Joos B, Weber R, Vernazza P, Hirschel B, Rauch A, Cavassini M, Bernasconi E, Battegay M, Kuster H, Niederöest B, Fischer M, Gianella S, the Swiss HIV Cohort Study (SHCS). Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. *PLoS one* 2011; 6:e27463.

von Wyl V, Günthard H, Ledergerber B, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Celleraï C, Shah C, Böni J, Yerly S, Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naïve individuals starting modern therapy combinations. *Clin Infect Dis* 2011; 54:131-40.

Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. *Clin Infect Dis* 2011; 53:1143-52.

von Wyl V, Günthard H, Bonhoeffer S, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Staehelin C, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Böni J, Yerly S, Kouyos R, Swiss HIV Cohort Study. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. *J Infect Dis* 2011; 204:1095-103.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 2011; 57:24–31.

Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals – the Swiss HIV Cohort Study. *J Transl Med* 2011; 9:14.

Kouyos R, Cavassini M, Rauch A, Battegay M, Vernazza P, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard H, Hirschel B, Weber R, Klimkait T, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Swiss HIV Cohort Study. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. *Clin Infect Dis* 2011; 52:532–9.

Gianella S, Günthard H, Joos B, Weber R, Vernazza P, Hirschel B, Rauch A, Cavassini M, Bernasconi E, Battegay M, Niederöst B, Fischer M, von Wyl V, the Swiss HIV Cohort Study. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. *Antivir Ther* 2011; 16:535–545.

Audigé A, Schlaepfer E, von Wyl V, Miller R, Vernazza P, Nadal D, Speck R, SHCS. B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF- α response to TLR9 triggering. *AIDS Res Hum Retroviruses* 2010; 26:1063–74.

Alizon S, Bonhoeffer S, Günthard H, Telenti A, Bürgisser P, Battegay M, Bernasconi E, Vernazza P, Rauch A, Furrer H, Klimkait T, Shah C, Böni J, Hirschel B, Yerly S, Kouyos R, Stadler T, von Wyl V, Swiss HIV Cohort Study. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. *PLoS Pathog* 2010; 6

Kouyos R, Bonhoeffer S, Ledergerber B, Rickenbach M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Taffé P, Böni J, Yerly S, von Wyl V, Günthard H. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. *J Infect Dis* 2010; 201:1488–97.

von Wyl V, Günthard H, Ledergerber B, Bonhoeffer S, Francioli P, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Yerly S, Swiss HIV Cohort Study. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 48:979–87.

von Wyl V, Günthard H, Ledergerber B, Rickenbach M, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2008; 46:1299–309.

Berger S, Weber R, Battegay M, Ledergerber B, Vernazza P, Regli D, Furrer H, Zellweger C, Ehlert U, von Wyl V, Schad T, Gaab J. Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. *AIDS (London, England)* 2008; 22:767–75.

Wolbers M, Bucher H, Günthard H, Yerly S, Battegay M, Bernasconi E, Vernazza P, Cavassini M, Furrer H, Hirschel B, von Wyl V, Opravil M, Swiss HIV Cohort Study. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. *AIDS (London, England)* 2007; 21:2201–7.

von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine 2007; 167:1782-90.

Zinkernagel A, Weber R, Schmid P, Bernasconi E, Opravil M, Tarr P, Hirschel B, Battegay M, Furrer H, Rickenbach M, Ledergerber B, von Wyl V, Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy 2006; 11:131-42.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch